JP2024527023A5 - - Google Patents
Info
- Publication number
- JP2024527023A5 JP2024527023A5 JP2024504808A JP2024504808A JP2024527023A5 JP 2024527023 A5 JP2024527023 A5 JP 2024527023A5 JP 2024504808 A JP2024504808 A JP 2024504808A JP 2024504808 A JP2024504808 A JP 2024504808A JP 2024527023 A5 JP2024527023 A5 JP 2024527023A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- therapy
- ovicetrapib
- use according
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21187721 | 2021-07-26 | ||
| EP21187721.2 | 2021-07-26 | ||
| PCT/EP2022/070780 WO2023006657A1 (en) | 2021-07-26 | 2022-07-25 | Treatment of his hyporesponders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527023A JP2024527023A (ja) | 2024-07-19 |
| JP2024527023A5 true JP2024527023A5 (https=) | 2025-07-03 |
Family
ID=77358089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024504808A Pending JP2024527023A (ja) | 2021-07-26 | 2022-07-25 | Ｈｉｓ低応答者の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230041138A1 (https=) |
| EP (1) | EP4376832B1 (https=) |
| JP (1) | JP2024527023A (https=) |
| KR (1) | KR20240040767A (https=) |
| CN (1) | CN117940125A (https=) |
| AU (1) | AU2022320869A1 (https=) |
| CA (1) | CA3227153A1 (https=) |
| IL (1) | IL310115A (https=) |
| MX (1) | MX2024001170A (https=) |
| WO (1) | WO2023006657A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12006305B2 (en) | 2022-07-05 | 2024-06-11 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
| WO2025146415A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Improvement in atherosclerotic plaque characteristics with obicetrapib |
| WO2026062050A1 (en) * | 2024-09-17 | 2026-03-26 | Newamsterdam Pharma B.V. | Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
| EP2846779A4 (en) | 2012-05-07 | 2015-12-16 | Omthera Pharmaceuticals Inc | STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS |
| ES2926775T3 (es) | 2014-08-12 | 2022-10-28 | Newamsterdam Pharma B V | Proceso de preparación de intermedios sintéticos para la preparación de derivados de tetrahidroquinolina |
| CA2959488C (en) | 2014-08-28 | 2023-06-20 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa reductase inhibitors |
-
2022
- 2022-07-25 MX MX2024001170A patent/MX2024001170A/es unknown
- 2022-07-25 CA CA3227153A patent/CA3227153A1/en active Pending
- 2022-07-25 WO PCT/EP2022/070780 patent/WO2023006657A1/en not_active Ceased
- 2022-07-25 AU AU2022320869A patent/AU2022320869A1/en active Pending
- 2022-07-25 EP EP22754412.9A patent/EP4376832B1/en active Active
- 2022-07-25 CN CN202280057367.XA patent/CN117940125A/zh active Pending
- 2022-07-25 JP JP2024504808A patent/JP2024527023A/ja active Pending
- 2022-07-25 IL IL310115A patent/IL310115A/en unknown
- 2022-07-25 KR KR1020247005859A patent/KR20240040767A/ko active Pending
- 2022-07-25 US US17/873,009 patent/US20230041138A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024527023A5 (https=) | ||
| RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
| JP2005510535A5 (https=) | ||
| JP2004531468A5 (https=) | ||
| JP2015526458A5 (https=) | ||
| JPH06102622B2 (ja) | 肥満の治療 | |
| JP2024507810A5 (https=) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| RU2011139643A (ru) | Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты | |
| RU2012110592A (ru) | Соединения и способ снижения мочевой кислоты | |
| JP2006503850A5 (https=) | ||
| TW202304424A (zh) | 包含依維莫司和安森司群的組合 | |
| IL310115A (en) | Treatment of his hyporesponders | |
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2023513220A5 (https=) | ||
| RU2008102911A (ru) | Фармацевтические составы на основе гуанфацина, подходящие для ежедневного введения в виде единичной дозированной формы | |
| JP2002544227A5 (https=) | ||
| JP2004525143A5 (https=) | ||
| JP2023531675A5 (https=) | ||
| JP2022177119A5 (https=) | ||
| Oettmeier et al. | The procainebase-infusion: 20 years of experience of an alternative use with several therapeutical effects | |
| JP2023538065A5 (https=) | ||
| WO2010092436A1 (en) | Pharmaceutical combinations of simethicone and otilonium | |
| JP2008528603A (ja) | ＰＰＡＲ−αモジュレータの製剤及び投与計画 | |
| RU2008108175A (ru) | Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы |